SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Approvals
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
May 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Woman taking retro photos. Digital collage with female hands holding vintage camera. Pop art design. Concept of social media
Mergers & acquisitions
UCB captures Candid in $2.2B autoimmune deal as pharma’s M&A train chugs along
Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion deal.
May 4, 2026
 · 
2 min read
 · 
Tristan Manalac
A surreal concept of a regular aluminium ladder pushing through a fluffy cloud on a peach sky background - 3D render
Obesity
Obesity ends oncology’s long reign as top contributor to biopharma pipeline value
In its latest biopharma pipeline report, Deloitte warned that the growing importance of a small pool of potential mega-blockbusters raises the risk of “significant value destruction from a single program failure.”
May 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.
May 4, 2026
 · 
4 min read
 · 
Tristan Manalac
Photo of pinned Raleigh on a map of USA. May be used as illustration for traveling theme.
Manufacturing
Novartis unveils North Carolina API plant as final piece of $23B US expansion
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.
May 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Court Filed Bankruptcy 3d illustration
Earnings
Moderna beats revenue expectations with $389M, but litigation dogs earnings
CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity.
May 1, 2026
 · 
3 min read
 · 
Annalee Armstrong
Calendar page flipping sheet close up blur background business schedule planning appointment meeting concept
Earnings
Amgen positions MariTide as potential ‘best monthly’ obesity drug
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.
May 1, 2026
 · 
2 min read
 · 
Tristan Manalac
Brain intelligence, fix or adjust creativity thinking, wisdom or improve knowledge learning, tune attitude level or idea development concept, man using wrench adjust gear cogwheels in human brain.
Approvals
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
May 1, 2026
 · 
2 min read
 · 
Tristan Manalac
Isolated vector design.
Neurodegenerative disease
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears
Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
May 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS